1.28
1.28 (0%)
As of Apr 17, 2025
Editas Medicine, Inc. [EDIT]
Source:
Company Overview
Editas Medicine, Inc. is a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 401-9000 |
| Industry | manufacturing |
| CEO | Gilmore O’Neill |
| Website | www.editasmedicine.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $32.3 |
| Operating Profit | $-251.2 |
| Net Income | $-237.1 |
| Net Cash | $7.9 |
Profit Ratios
| Gross Margin | $32.3 |
| Operating Margin | -777.2 |
| Profit as % of Revenues | -13.6% |
| Profit as % of Assets | -56.4% |
| Profit as % of Stockholder Equity | -176.6% |
Management Effectiveness
| Return on Equity | -176.6% |
| Return on Assets | -69.4% |
| Turnover Ratio | 7.7% |
| EBITA | $-251.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $341.6 |
| Total Liabilities | $207.3 |
| Operating Cash Flow | $-210.3 |
| Investing Cash Flow | $162.1 |
| Financing Cash Flow | $56 |
